Moleculin Biotech Secures $5.9M to Accelerate Next-Generation Cancer and Viral Treatments

Moleculin Biotech, Inc. (NASDAQ: MBRX) has exciting news to share with investors and the biomedical community as it successfully raised $5,900,000 in its latest funding round. This injection of capital signifies strong stakeholder confidence in the company's innovative approach to addressing critical challenges in oncology and virology. As a clinical stage pharmaceutical firm, Moleculin Biotech is dedicated to developing breakthrough drug candidates aimed at treating highly resistant tumors and viruses. With its diversified pipeline, the company is setting a new standard in precision medicine and targeted therapies. This round of funding is strategically aimed at accelerating the development and clinical evaluation of Moleculin’s promising lead program, Annamycin—a next-generation anthracycline engineered to bypass multidrug resistance mechanisms while minimizing cardiotoxic risks. Annamycin is currently being studied for its potential in treating soft tissue sarcoma lung metastases and relapsed or refractory acute myeloid leukemia, showcasing its potential to transform patient outcomes in these challenging areas. In addition, the capital will support the advancement of Moleculin’s innovative portfolio of antimetabolites, including WP1122, designed for combating COVID-19 and other viral infections, as well as various cancer indications such as brain and pancreatic cancer. The funding will also bolster efforts to further develop WP1066, an Immune/Transcription Modulator targeting oncogenic pathways in brain tumors and other cancers, along with its analogue WP1220 for treating cutaneous T-cell lymphoma. Overall, this funding milestone not only underscores investor confidence in Moleculin’s scientific vision and clinical potential but also solidifies the company’s commitment to delivering transformative therapies for unmet medical needs.